Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.

Research and development (R&D) are essential elements of Eli Lilly’s operations, enabling the company to remain at the ...

Eli Lilly operates in the healthcare sector as a global pharmaceutical manufacturer with commercial medicines and a broad research portfolio across immunology, oncology, and metabolic health. Eli ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Nvidia shares tick up as investors await the chip maker’s fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up.

Shares of Eli Lilly & Co. LLY slid 1.34% to $1,009.52 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.69% to 6,909.51 and ...

This was the stock's second consecutive day of losses.

Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised its quarterly dividend 15% to $1.73 per share. The ...

Market confidence amid sustained momentum, shifting sector leadership, and expectations of continued gains have helped the S&P 500 deliver strong performance over a prolonged peri ...